Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.47 |
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22143468 | 0.91 | LIPG (0.55) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL15305893 | 0.90 | LIPG (0.49) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL21157799 | 0.88 | LIPG (0.58) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL21974388 | 0.88 | LIPG (0.58) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL16225068 | 0.87 | LIPG (0.52) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL12415371 | 0.87 | LIPG (0.56) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL29848429 | 0.87 | LIPG (0.56) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL24639795 | 0.87 | LIPG (0.56) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL21795304 | 0.85 | LIPG (0.54) | LIPGLPLKDM4EATML3MBTL1 | |
| SCHEMBL16666064 | 0.85 | LIPG (0.54) | LIPGLPLKDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4271163-A2 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | Merck Patent GmbH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-11711976-B2 | Compounds with an acceptor and a donor group | MERCK PATENT GMBH (DE) | 2023-07-25 | — | — | US | disclosed |
| US-11711976-B2 | Compounds with an acceptor and a donor group | MERCK PATENT GMBH (DE) | 2023-07-25 | — | — | US | disclosed |
| US-20200203624-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| WO-2018087346-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11711976-B2 | Compounds with an acceptor and a donor group | NQO1, ICMT, NUDT1 | LIPG 1743/4885LPL 3991/4885KDM4E 2457/4885 |
| US-20200203624-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | NQO1, ICMT, NUDT1 | LIPG 1743/4885LPL 3991/4885KDM4E 2457/4885 |
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | NQO1, ICMT, NUDT1 | LIPG 1743/4885LPL 3991/4885KDM4E 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.